• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2013 - Product Image

Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2013

  • ID: 2686624
  • October 2013
  • 134 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Eisai Co., Ltd.
  • ELORAC, Inc.
  • Galderma S.A.
  • Innate Pharma SA
  • Johnson & Johnson
  • Mondobiotech Holding AG
  • MORE

Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma. Cutaneous T-Cell Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cutaneous T-Cell Lymphoma.
- A review of the Cutaneous T-Cell Lymphoma products under development READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Eisai Co., Ltd.
  • ELORAC, Inc.
  • Galderma S.A.
  • Innate Pharma SA
  • Johnson & Johnson
  • Mondobiotech Holding AG
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Cutaneous T-Cell Lymphoma Overview
Therapeutics Development
An Overview of Pipeline Products for Cutaneous T-Cell Lymphoma
Cutaneous T-Cell Lymphoma Therapeutics under Development by Companies
Cutaneous T-Cell Lymphoma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Cutaneous T-Cell Lymphoma Therapeutics - Products under Development by Companies
Cutaneous T-Cell Lymphoma Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Cutaneous T-Cell Lymphoma Therapeutics Development
Johnson & Johnson
Kyowa Hakko Kirin Co., Ltd.
Seattle Genetics, Inc.
Emergent BioSolutions Inc.
Millennium Pharmaceuticals, Inc.
Novartis AG
Eisai Co., Ltd.
Galderma S.A.
Onyx Pharmaceuticals, Inc.
Mundipharma International Limited
Innate Pharma SA
Spectrum Pharmaceuticals, Inc.
Chipscreen Biosciences Ltd
Mondobiotech Holding AG
Yaupon Therapeutics, Inc.
ELORAC, Inc.
Cutaneous T-Cell Lymphoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
brentuximab vedotin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
panobinostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HBI-8000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bortezomib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
carfilzomib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
everolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mogamulizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
forodesine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pralatrexate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IPH-41 Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
zanolimumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
quisinostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anti-Tac(Fv)-PE38 Immunotoxin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
naloxone hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DNA IL-12 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SHP-141 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Angeloxin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CD-5789 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Genetically Modified T Cells-1138 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
K-777 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cutaneous T-Cell Lymphoma Therapeutics - Drug Profile Updates
Cutaneous T-Cell Lymphoma Therapeutics - Discontinued Products
Cutaneous T-Cell Lymphoma Therapeutics - Dormant Products
Cutaneous T-Cell Lymphoma - Product Development Milestones
Featured News & Press Releases
Aug 26, 2013: Ceptaris Receives FDA Approval for VALCHLOR Gel for the Treatment of Stage IA and IB Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma in Patients Who Have Received Prior Skin-Directed Therapy
Aug 08, 2013: FDA Grants Orphan Drug Status To Eisai's Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
Jul 24, 2013: Inovio Pharmaceuticals' Potent hTERT DNA Cancer Vaccine Shows Potential to Reduce Tumors and Prevent Tumor Recurrence
Jul 19, 2013: Application Seeking Approval for Additional Indication for ATL, PTCL and CTCL of Mogamulizumab
Apr 12, 2013: Elorac's Naloxone Topical Lotion Receives FDA Fast Track Designation For Relief Of Pruritus In Patients With Cutaneous T-cell Lymphoma
Mar 04, 2013: Shape Pharma Provides Update On SHP-141 Topical HDAC Inhibitor Clinical Development For Cutaneous T Cell Lymphoma
Feb 27, 2013: Ceptaris Resubmits New Drug Application To FDA For Gel Formulation Of Mechlorethamine Hydrochloride
Dec 13, 2012: Kyowa Hakko Kirin Initiates Pivotal Phase III Trial Of Mogamulizumab In Patients With Cutaneous T-Cell Lymphoma In US
Dec 11, 2012: Kyowa Hakko Kirin Announces Presentation Of Phase II Clinical Trial Results Of Mogamulizumab At ASH Annual Meeting
Dec 10, 2012: Seattle Genetics Presents Data From Two Phase II Studies Of Adcetris In Cutaneous T-Cell Lymphoma At ASH Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Cutaneous T-Cell Lymphoma, H2 2013
Products under Development for Cutaneous T-Cell Lymphoma - Comparative Analysis, H2 2013
Number of Products under Development by Companies, H2 2013
Number of Products under Investigation by Universities/Institutes, H2 2013
Comparative Analysis by Late Stage Development, H2 2013
Comparative Analysis by Mid Clinical Stage Development, H2 2013
Comparative Analysis by Early Clinical Stage Development, H2 2013
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013
Products under Development by Companies, H2 2013
Products under Investigation by Universities/Institutes, H2 2013
Johnson & Johnson, H2 2013
Kyowa Hakko Kirin Co., Ltd., H2 2013
Seattle Genetics, Inc., H2 2013
Emergent BioSolutions Inc., H2 2013
Millennium Pharmaceuticals, Inc., H2 2013
Novartis AG, H2 2013
Eisai Co., Ltd., H2 2013
Galderma S.A., H2 2013
Onyx Pharmaceuticals, Inc., H2 2013
Mundipharma International Limited, H2 2013
Innate Pharma SA, H2 2013
Spectrum Pharmaceuticals, Inc., H2 2013
Chipscreen Biosciences Ltd, H2 2013
Mondobiotech Holding AG, H2 2013
Yaupon Therapeutics, Inc., H2 2013
ELORAC, Inc., H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Stage and Molecule Type, H2 2013
Cutaneous T-Cell Lymphoma Therapeutics - Drug Profile Updates
Cutaneous T-Cell Lymphoma Therapeutics - Discontinued Products
Cutaneous T-Cell Lymphoma Therapeutics - Dormant Products
Cutaneous T-Cell Lymphoma Therapeutics - Dormant Products (Contd..1)

List of Figures
Number of Products under Development for Cutaneous T-Cell Lymphoma, H2 2013
Products under Development for Cutaneous T-Cell Lymphoma - Comparative Analysis, H2 2013
Products under Development by Companies, H2 2013
Products under Investigation by Universities/Institutes, H2 2013
Late Stage Products, H2 2013
Mid Clinical Stage Products, H2 2013
Early Clinical Stage Products, H2 2013
Discovery and Pre-Clinical Stage Products, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Route of Administration, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Molecule Type, H2 2013
Assessment by Stage and Molecule Type, H2 2013 40

Note: Product cover images may vary from those shown

Johnson & Johnson
Kyowa Hakko Kirin Co., Ltd.
Seattle Genetics, Inc.
Emergent BioSolutions Inc.
Millennium Pharmaceuticals, Inc.
Novartis AG
Eisai Co., Ltd.
Galderma S.A.
Onyx Pharmaceuticals, Inc.
Mundipharma International Limited
Innate Pharma SA
Spectrum Pharmaceuticals, Inc.
Chipscreen Biosciences Ltd
Mondobiotech Holding AG
Yaupon Therapeutics, Inc.
ELORAC, Inc.

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos